Caught Out By Alexandria Real Estate? What The Bears Saw

If you had hesitated over Alexandria Real Estate Equities on 23 October 2025, wondering whether the life science REIT story was worth the risk, the next twelve months gave a harsh answer. For Alexandria Real Estate Equities shareholders, the loss over the past year was 41.1%, including dividends. With that outcome now clear, which assumptions on record back then about financing costs, occupancy, or lab demand most needed a closer look?

Alexandria Real Estate Equities has already moved. See which of 27 high quality undervalued stocks still trade below our estimates.

The Two Stories Investors Were Weighing On Alexandria Real Estate Equities

The shares cost US$76.91 at the start of the period, and anyone looking at Alexandria Real Estate Equities then had to decide which story felt more realistic.

The bullish narrative pointed to a Fair Value of US$97.5, a price implied by assumptions about the future, built on aging demographics and rising healthcare R&D supporting demand for lab space and long leases in Boston, San Diego, and San Francisco.

The bearish view anchored on a Fair Value of US$71, with higher financing costs and persistent hybrid work seen as threats to occupancy, rental growth, and margins in key biotech hubs.

What The Results Changed For The Alexandria Real Estate Equities Debate

The clearest signal came from Alexandria Real Estate Equities cutting its dividend by 45% and shrinking its development pipeline while planning more than US$1.8b of property sales, which leaned toward the cautious financing story. Q2 2026 revenue of US$663.2m was lower than Q2 2025, yet the firm still reported a smaller loss and a less negative net margin. The evidence cut both ways.

The big lesson is simple. When the question is about funding costs and balance sheet strain, track management actions on dividends, development spend, and asset sales, and then compare those decisions with changes in net margin and interest expense at any other REIT you are assessing.

What You Are Really Buying With Alexandria Real Estate Equities Today

At a share price of US$43.02, Alexandria Real Estate Equities trades well below the Narrative's Fair Value, which the Narrative frames as higher than the current market level rather than a hard fact.

That view leans on resilient life science campuses, ongoing cash generation, and a balance sheet the Narrative still calls solid. For the fall to look like an opening instead of a warning, a buyer today would need to believe occupancy and lab demand can support the current development pipeline and debt load.

"Given these risks, we apply a margin of safety to NAV. Under the StockWatch methodology, this typically ranges from 0 to 35%."

Not everyone reads the same price the same way. → See the higher figure this Narrative lands on, and how it gets there

Looking Beyond Alexandria’s Lab Space

Alexandria Real Estate Equities focuses on physical science campuses and lab environments.

It is natural to watch buildings, tenants, and financing closely there.

One layer out, researchers still need computing power, storage, and dependable network connections.

Another business concentrates on that digital plumbing, supplying chips and software to move, secure, and manage data.

Growing use of AI, enterprise tools, and connected devices keeps pointing toward its role as data workloads expand in scale and complexity.

The argument comes with a number attached. → Uncover the AI infrastructure company trading 51% below one Narrative's Fair Value

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com